

## Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.

Per June 16, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 23,532,753 shares, corresponding to 5.02% (previously 4.85%) of the total share capital attached to shares. The combined total of share capital attached to shares and share capital through financial instruments is 5.12% (previously 5.00%).

**June 19, 2025**

Company announcement No. 32

### Contact information

---

Tobias Bjorklund

+45 3077 8682

[tobb@novonesis.com](mailto:tobb@novonesis.com)

Anders Enevoldsen

+45 5350 1453

[adev@novonesis.com](mailto:adev@novonesis.com)

Katrine Spedtsberg Poulsen

[kats@novonesis.com](mailto:kats@novonesis.com)

---

### About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

### Novozymes A/S, part of Novonesis Group

Krogshøjvej 36  
2880 Bagsvaerd  
Denmark